PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer

DISEASE CHARACTERISTICS:

Histological confirmation of 1 of the following:

Ovarian epithelial carcinoma
Fallopian tube cancer
Primary peritoneal cancer
Advanced colorectal carcinoma
Other malignancy confined to the peritoneal cavity or peritoneal surfaces
No lesion greater than 2 cm in greatest diameter based on surgical re-assessment
Low burden of tumor in the abdominal or pelvic cavities and no clinically significant ascites
Received potentially effective therapy when available (e.g., platinum/taxane for ovarian cancer, fluoropyrimidine-based therapy for colorectal cancer)
No concurrent hematological malignancy (e.g., chronic lymphocytic leukemia or non-Hodgkin's lymphoma)
No bilateral adrenal metastases
No adrenal metastases in the remaining adrenal gland after adrenalectomy (including radical nephrectomy)
No lung tumors 5 cm or more
No pleural effusions (at least 25% of hemithorax) by radiography
No CNS metastases by CT scan or MRI

PATIENT CHARACTERISTICS:

Age

18 and over

Performance status

Karnofsky 70-100%

Life expectancy

More than 3 months

Hematopoietic

WBC at least 3,000/mm^3
Absolute neutrophil count at least 1,000/mm^3
Platelet count at least 100,000/mm^3
Hemoglobin greater than 9 g/dL

Hepatic

Bilirubin no greater than 1.5 times upper limit of normal (ULN)
AST and ALT no greater than 1.5 times ULN
Alkaline phosphatase no greater than 1.5 times ULN
No uncontrolled hepatic dysfunction
No active hepatitis B or C

Renal

See Disease Characteristics
Creatinine no greater than 1.6 mg/dL AND/OR
Creatinine clearance at least 50 mL/min
No uncontrolled renal dysfunction

Cardiovascular

No uncontrolled cardiovascular dysfunction
No myocardial infarction within the past 6 months
No life-threatening arrhythmias within the past 6 months

Pulmonary

See Disease Characteristics
No uncontrolled pulmonary dysfunction
No pulmonary atelectasis (lobar)
No pulmonary infiltrates (lobar)
No pulmonary consolidation (lobar or segmental)
No baseline grade II dyspnea

Adrenal

See Disease Characteristics
No uncontrolled adrenal dysfunction
No known adrenal insufficiency

Other

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
No uncontrolled gastrointestinal dysfunction
No neurological dysfunction
No serious medical or psychological condition that would preclude study participation or increase the risk of adverse effects of the study treatment
No history of serious immunodeficiency
No active uncontrolled bacterial infection (including asymptomatic urinary tract infection)

No contraindication to intraperitoneal therapy including the following:

Intra-abdominal infection
Dense widespread adhesions
Peritonitis
Periumbilical infection
Bowel obstruction
Ileostomy
No hypersensitivity to eggs
No continued contact with live birds (e.g., poultry farmers, veterinarians, laboratory technicians, pet store owners, breeders)

PRIOR CONCURRENT THERAPY:

Biologic therapy

Not specified

Chemotherapy

See Disease Characteristics
No more than 3 prior cytotoxic chemotherapy regimens
More than 30 days since prior chemotherapy

Endocrine therapy

More than 14 days since prior systemic corticosteroids

Radiotherapy

More than 30 days since prior radiotherapy

Surgery

See Disease Characteristics
No prior complete or partial lobectomy with removal of lung tissue at least segmental size
No prior organ allograft

Other

Recovered from prior therapy
More than 14 days since prior antiviral medication
More than 4 weeks since prior immunosuppressive drugs
No other concurrent investigational drugs
No concurrent chronic immunosuppressive drugs (e.g., cyclosporine)
No vaccination for influenza within 48 hours of study drug administration
No concurrent hypoglycemic agents
No concurrent antiretroviral therapy for HIV-positive patients
No other concurrent anticancer therapy